Results 161 to 170 of about 8,557 (171)

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Expert Opinion on Biological Therapy, 2020
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD).
Tommaso Lorenzo Parigi, Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese   +3 more
openaire   +2 more sources

Infliximab biosimilar CT-P13 in Crohn's disease

The Lancet, 2019
Gecse, Krisztina B., D'Haens, Geert R.
openaire   +3 more sources

Infliximab biosimilar CT-P13 for inflammatory bowel disease

The Lancet Gastroenterology & Hepatology, 2018
Bonovas S, Peyrin-Biroulet L, Danese S
openaire   +3 more sources

CT-P13 (an infliximab biosimilar): a guide to its use in the EU

Drugs & Therapy Perspectives, 2015
CT-P13 (Remsima™; Inflectra™) is an infliximab biosimilar approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +1 more source

Biosimilars and inflammatory bowel disease: a switch programme using CT-P13

Pharmaceutical Journal, 2016
openaire   +2 more sources

Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13

Arthritis & Rheumatism, 2013
Yoo, Dae-Hyun, Prodanovic, Nenad, Jaworski, Janusz, Miranda, Pedro, Ramiterre, Edgar, Lanzon, Allan, Baranauskaite, Asta, Abud-Mendoza, Carlos, Oparanov, Boycho, Smiyan, Svitlana, Son, YoungKi, Park, Won, Muller-Ladner, Ulf   +12 more
openaire  

Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13

Arthritis & Rheumatism, 2013
Park, Won, Miranda, Pedro, Brzosko, Marek, Gutierrez-Urena, Sergio, Mikazane, Helena, Lee, Yeon-Ah, Smiyan, Svitlana, Lim, Mie-Jin, Kadinov, Vladimir, Abud-Mendoza, Carlos, Son, YoungKi, Yoo, Dae-Hyun, Braun, Jurgen   +12 more
openaire  

Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Gastroenterology, 2017
Fiorino G, Ruiz-Aguello MB, Maguregui A, Nagore D, Radice S, Gilardi D, Correale C, Allocca M, Furfaro F, Alfieri M, Martinez A, Danese S   +11 more
openaire   +2 more sources

Effectiveness and Safety in Crohn's Disease Patients who were Treated with CT-P13

Gastroenterology, 2017
Yon Ho Choe, Suck-Ho Lee, Dongil Park, Ji Hyun Lee, Hyo-Jong Kim, Young Ho Kim, Chang Hwan Choi, Chang Soo Eun, Sang Joon Lee, Sunhee Lee   +9 more
openaire   +1 more source

Optimizing CT-P13 SC Use in IBD: ADA Formation, Comparative Efficacy, and Dose Adjustment Strategies

Gastroenterology
Xiaolei, Zhao, Dan, Shan, Jiashu, Han
openaire   +2 more sources